CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ — Insilico Medicine (HKEX: 3696.HK, “Insilico” or the “Company”), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results for the year ended December 31, 2025, and provide a business update on March 30, 2026. The Company will hold live conference calls in English and Mandarin on March 30, 2026, Beijing Time.

The English session of the conference call will be held at 9:00 AM on March 30, 2026, Beijing Time (9:00 PM U.S. Eastern Time on March 29, 2026), and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (10:30 PM U.S. Eastern Time on March 29, 2026).

The conference calls can be accessed by the following links:

For English Session:

Time: 9:00 AM Beijing Time, Monday, March 30, 2026
(9:00 PM U.S. Eastern Time, Sunday, March 29, 2026)

Register and Webcast Link:

https://insilico.zoom.us/w/81195639919?pwd=i153PUfkONs5INk8mgvLmmttveLqc0.1

Participants are required to pre-register for the English conference call using the link above. After registration is approved, participants will receive the webinar access link and dial-in information via email.

For Mandarin Session:

Time: 10:30 AM Beijing Time, Monday, March 30, 2026
(10:30 PM U.S. Eastern Time, Sunday, March 29, 2026)

Register and Webcast Link:
https://research.citics.com/tel/info/1_2047925

Participants are required to pre-register for the Mandarin conference call using the link above.

Alternatively, participants may dial in to the conference call using below dial-in information:

The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at https://insilico.com/.

HONG KONG, March 13, 2026 /PRNewswire/ —  Approximately 40% of the East Asian population suffers from alcohol intolerance, commonly known as “Asian Flush Syndrome”. This ALDH2 genetic mutation is more than just a metabolic defect; it conceals a deadly cardiovascular risk. While the medical community has long observed that carriers of this mutation suffer more severe heart damage during a myocardial infarction (heart attack), the specific underlying mechanism has remained a mystery until now.

A research team led by Professor Yin Huiyong, Professor in the Department of Biomedical Sciences at City University of Hong Kong (CityUHK), recently published a groundbreaking study in Circulation, a top-tier journal in cardiovascular medicine. Titled “ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury”, the research reveals for the first time how the ALDH2 mutation triggers “ferroptosis”—a specific type of cell death—during heart attacks, leading to a rapid deterioration of cardiac tissue. This discovery opens new doors for precision prevention and treatment for hundreds of millions of gene carriers worldwide.

The study highlights that the ALDH2 mutation does not only impair alcohol metabolism but also significantly worsens heart damage during acute myocardial infarction. The team carried out a clinical study of 177 Chinese patients with acute heart failure, and found that those carrying the ALDH2 mutation exhibited much more severe cardiac dysfunction following a heart attack. In this study, the team observed clear signs of ferroptosis in these patients, including a significant drop in Coenzyme Q10 (a cardio-protective antioxidant) and a massive accumulation of bioactive lipids that cause oxidative damage to cells.

Ferroptosis is a form of cell death driven by iron ions and lipid peroxidation. For the heart, this death process acts like a chain reaction, delivering an irreversible and devastating blow to myocardial cells, eventually leading to severe acute heart failure.

The key scientific breakthrough of this study lies in identifying the ALDH2 protein’s hidden role as a cellular “regulator”. Under normal conditions, ALDH2 binds with the eIF3E subunit (part of the complex responsible for protein synthesis), acting like a “security lock” to maintain protein balance within the cell. However, in the presence of the ALDH2 mutation, structural changes cause this lock to fail. The released eIF3E then enters a “selective mode”, prompting ribosomes to mass-produce pathogenic proteins that induce ferroptosis. This role reversal—from a “metabolic enzyme” to a “translational regulator”—explains why individuals with the “flushing gene” suffer significantly more heart damage when facing the same level of myocardial ischemia.

To verify these mechanisms and identify therapeutic opportunities, the team conducted experiments using animal models. The results demonstrated that either inhibiting the ferroptosis process via medication or using genetic technology to regulate the protein translation pathway could significantly improve heart function in mice carrying the ALDH2 mutation after a heart attack. This suggests that existing iron chelators or specific ferroptosis inhibitors have immense potential to be developed into protective therapies specifically for East Asian populations.

The study redefines the physiological role of ALDH2 in cardiac protection and underscores the vital importance of precision medicine in treating cardiovascular diseases. In the future, clinicians may be able to use genetic testing to identify high-risk ALDH2 carriers and implement “anti-ferroptosis” interventions early to predict and improve outcomes for heart attack patients.

Other institutions participating in this joint study include Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, the Naval Medical University, Sun Yat-sen University, Fudan University, and Harbin Medical University. The research was supported by the National Natural Science Foundation of China, the Shenzhen Medical Research Fund, the Research Grants Council of Hong Kong, and CityUHK.

The global impact of this research is further highlighted by a dedicated editorial commentary in the same issue of Circulation. Entitled “Selective mRNA Translation: A New Player in Ferroptosis After Myocardial Infarction“, the piece is authored by Professor Yi Zhu, a renowned scientist in the cardiovascular field from Tianjin Medical University. Such a commentary is a significant honour, reserved for studies that provide transformative insights and open new frontiers in medical science.

BEIJING, March 13, 2026 /PRNewswire/ — Recon Technology, Ltd (NASDAQ: RCON) (“Recon” or the “Company”), a China-based independent solutions integrator in the oilfield service and environmental protection, electric power and coal chemical industries, today announced its financial results for the first six months of fiscal year 2026.

First Six Months of Fiscal 2026 Financial Highlights:

• Total revenue increased to RMB85.0 million ($12.2 million) for the six months ended December 31, 2025, from RMB42.0 million ($5.8 million) for the same period in 2024.
• Gross profit increased to RMB28.5 million ($4.1 million) for the six months ended December 31, 2025, from RMB13.4 million ($1.9 million) for the same period in 2024.
• Gross margin increased to 33.5% for the six months ended December 31, 2025 from 31.7% for the same period in 2024.
• Net loss was RMB7.2 million ($1.0 million) for the six months ended December 31, 2025, a decrease of RMB13.5 million ($1.9 million) from net loss of RMB20.7 million ($3.0 million) for the same period of 2024.

Management Commentary

Mr. Shenping Yin, Founder and CEO of Recon, stated: “We are encouraged by the significant progress the Company has made during the first half of fiscal year 2026. For the six months ended December 31, 2025, Recon’s core business remained stable and achieved substantial growth, primarily driven by the successful execution of overseas oilfield projects and the recovery of domestic oilfield production activities. Furthermore, Recon remains committed to diversifying its revenue streams and seizing opportunities in the circular economy. The Company’s plastic chemical recycling project, launched in 2023, continues to progress on schedule. The project, which is expected to be fully completed by July 2026, will position Recon to capitalize on the growing demand for sustainable and recycled materials, aligning with global ESG trends and creating long-term value for shareholders. “

Mr. Yin continued, “Amid a dynamic global energy market characterized by supply-demand rebalancing and evolving industry changes, the Company has demonstrated resilience and adaptability, leveraging its core strengths to drive revenue growth while navigating operational challenges. Our focus on high-value-added services, strategic diversification, and operational excellence will continue to guide our decisions as we pursue our long-term growth objectives.”

Recon Technology remains committed to delivering innovative, reliable solutions to its customers while upholding the highest standards of corporate governance and social responsibility. The Company will continue to provide timely updates on its business progress and financial performance as it executes its strategic plan.

First Six Months Fiscal 2026 Financial Results:

Revenue

Total revenues for the six months ended December 31, 2025 were approximately RMB85.0 million ($12.2 million), an increase of approximately RMB43.0 million ($6.2 million) or 102.2% from RMB42.0 million ($6.0 million) for the same period in 2024.

• Revenue from automation product and software increased by RMB41.4 million ($5.9 million) or 197.6%. For the six months ended December 31, 2025, the increase in revenue from automation products and software was primarily driven by the Company’s RMB44.2 million overseas oilfield projects during the period. This was a consequence of the second phase of oilfield capacity construction and the launch of a major automation service and maintenance project that we secured outside China in 2012. The growth was partially offset by a decline of RMB2.7 million in the domestic oilfield business, due to reduced maintenance efforts in the domestic market during the six months period, as our focus shifted towards overseas projects. Looking ahead, we will be making a particular shift in our personnel, moving them from overseeing markets to strengthening our domestic market maintenance.
• Revenue from equipment and accessories increased by RMB1.6 million ($0.2 million) or 10.2 %. For the six months ended December 31, 2025, the increase was primarily driven by a RMB4.1 million growth contributed by offshore oilfield operations, as well as revenues of about RMB1.2 million from new onshore oilfield customers. This increase offset some of the RMB3.7 million revenue decline due to reduced business from some occasional orders we achieved in the compared period.
• Revenue from oilfield environmental protection services increased by RMB2.8 million ($0.4 million), or 101.3%. This growth was primarily driven by the increase of settlement prices of some wastewater treatment clients.
• Revenue from platform outsourcing services decreased by RMB2.7 million ($0.4 million) or 100%. FGS’s operations were materially and adversely affected by strategic shifts in its major clients’ business decisions to terminate online cooperation of third-party companies and unfavorable changes in domestic industry policies. Consequently, FGS’s revenue and active business activities declined precipitously, resulting in zero revenue for the six months ended December 31, 2025.

Cost of revenue

Cost of revenues increased from RMB28.7 million ($4.1 million) for the six months ended December 31, 2024 to RMB56.6 million ($8.1 million) for the same period in 2025.

• For the six months ended December 31, 2024 and 2025, cost of revenue from automation product and software was approximately RMB12.4 million and RMB40.7 million ($5.8 million), respectively, representing an increase of approximately RMB28.3 million ($4.0 million) or 228.6%. The increase in cost of revenue from automation product and software was primarily attributable to increased revenue of automation products and software.
• For the six months ended December 31, 2024 and 2025, cost of revenue from equipment and accessories was approximately RMB11.2 million and RMB13.2 million ($1.9 million), respectively, representing an increase of approximately RMB2.0 million ($0.3 million) or 18.0%. The increase in costs of revenue was primarily driven by expanded business activity, mirroring the same factor behind the growth in revenue.
• For the six months ended December 31, 2024 and 2025, cost of revenue from oilfield environmental protection was approximately RMB4.8 million and RMB2.7 million ($0.4 million), respectively, representing a decrease of approximately RMB2.1 million ($0.3 million) or 43.7%. While actively pursuing new business opportunities in a constrained market, the Company undertook testing projects. Given their high uncertainty, equipment costs for these projects were fully costing upon purchase in the prior period, resulting in lower costs in the current period compared to the prior period.
• For the six months ended December 31, 2024 and 2025, the reason for the decrease is consistent with that of the revenue decline.

Gross profit

Gross profit increased to RMB28.5 million ($4.1 million) for the six months ended December 31,2025 from RMB13.4 million ($1.9 million) for the same period in 2024. Our gross profit as a percentage of revenue increased to 33.5% for the six months ended December 31, 2025 from 31.7% for the same period in 2024.

• For the six months ended December 31, 2024 and 2025, gross profit from automation products and software was approximately RMB8.5 million and RMB21.6 million ($3.1 million), respectively. This represents an increase of approximately RMB13.1 million ($1.9 million), or 152.8%, primarily driven by the Company’s overseas oilfield projects. However, the overall gross margin declined during the period due to a higher proportion of hardware revenue, which carries a lower gross margin.
• For the six months ended December 31, 2024 and 2025, gross profit from equipment and accessories was approximately RMB4.5 million and RMB4.1 million ($0.6 million), respectively, representing a decrease of approximately RMB0.4 million ($0.1 million) or 8.8%. The gross margin for automation equipment and accessories has remained relatively stable in this period.
• For the six months ended December 31, 2024 and 2025, gross profit from oilfield environmental protection services was approximately negative RMB2.1 million and RMB2.7 million ($0.4 million), respectively, representing an increase of RMB4.9 million ($0.7 million), or 229.1%. The higher costs in the prior period were primarily due to testing projects conducted in 2024, for which equipment costs were fully expensed upon purchase.
• For the six months ended December 31, 2024 and 2025, gross profit from platform outsourcing services was approximately RMB2.4 million and nil, respectively, representing a decrease of approximately RMB2.4 million ($0.3 million), or 100%, primarily due to the suspension of operations.

Operating expenses

Selling expenses decreased by 16.2%, or RMB0.9 million ($0.1 million), from RMB5.2 million for the six months ended December 31, 2024 to RMB4.3 million ($0.6 million) in the same period of 2025.

General and administrative expenses increased by 19.3%, or RMB4.6 million ($0.7 million), from RMB24.0 million for the six months ended December 31, 2024 to RMB28.7 million ($4.1 million) in the same period of 2025.

The Company also recorded allowance for credit losses of RMB0.9 million for the six months ended December 31, 2024 as compared to net recovery of credit losses of RMB0.02 million ($0.003 million) for the same period in 2025.

Research and development expenses decreased by 22.1%, or RMB2.2 million ($0.3 million) from RMB10.2 million for the six months ended December 31, 2024 to RMB7.9 million ($1.1 million) for the same period of 2025.

Loss from operations

Loss from operations was RMB12.4 million ($1.8 million) for the six months ended December 31, 2025, compared to a loss of RMB26.9 million for the same period of 2024. This RMB14.5 million ($2.1 million) decrease in operating losses was mainly driven by higher operating gross profit, as previously discussed.

Change in fair value of warrant liability

The Company classified the warrants issued in connection with common share offering as liabilities at their fair value and adjusted the warrant instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. Change in fair value changes of warrant liability was negative RMB10,327 and RMB584.0 ($84.0) for the six months ended December 31, 2024 and 2025, respectively. The primary reason for the decrease in the fair value loss of the warrant liability was the change in the fair value assessment price.

Interest income

Net interest income was RMB6.4 million ($0.9 million) for the six months ended December 31, 2025, compared to net interest income of RMB6.6 million for the same period of 2024. Interest income remained relatively stable.

Other expenses, net.

Other net expenses amounted to RMB1.2 million ($0.2 million) for the six months ended December 31, 2025, compared to RMB0.4 million for the same period in 2024, representing an increase of RMB0.8 million ($0.1 million). The increase was primarily due to the closure of Qinghai BHD and the disposal of 51% equity interest in MSJ, which together resulted in a total loss on equity shares investments of RMB1.1 million.

Net loss

As a result of the factors described above, net loss was RMB7.2 million ($1.0 million) for the six months ended December 31, 2025, a decrease of RMB13.5 million ($1.9 million) from net loss of RMB20.7 million for the same period of 2024.

Cash and short-term investment

As of December 31, 2025, we had cash in the amount of approximately RMB75.1 million ($10.7 million).As of June 30, 2025, we had cash in the amount of approximately RMB98.9 million ($14.1 million) and short-term investment in bank fixed income product of approximately RMB3.6 million ($0.5 million).

About Recon Technology, Ltd (“RCON”)

Recon Technology, Ltd (NASDAQ: RCON) is the People’s Republic of China’s first NASDAQ-listed non-state owned oil and gas field service company. Recon supplies China’s largest oil exploration companies, with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measure for increasing petroleum extraction levels, reducing impurities and lowering production costs. Through the years, RCON has taken leading positions within several segmented markets of the oil and gas filed service industry. RCON also has developed stable long-term cooperation relationship with its major clients. For additional information please visit: http://www.recon.cn/.

Forward-Looking Statements

Recon includes “forward-looking statements” within the meaning of the federal securities laws throughout this press release. A reader can identify forward-looking statements because they are not limited to historical fact or they use words such as “scheduled,” “may,” “will,” “could,” “should,” “would,” “expect,” “believe,” “anticipate,” “project,” “plan,” “estimate,” “forecast,” “goal,” “objective,” “committed,” “intend,” “continue,” or “will likely result,” and similar expressions that concern Recon’s strategy, plans, intentions or beliefs about future occurrences or results. Forward-looking statements are subject to risks, uncertainties and other factors that may change at any time and may cause actual results to differ materially from those that Recon expected. Many of these statements are derived from Recon’s operating budgets and forecasts, which are based on many detailed assumptions that Recon believes are reasonable, or are based on various assumptions about certain plans, activities or events which we expect will or may occur in the future. However, it is very difficult to predict the effect of known factors, and Recon cannot anticipate all factors that could affect actual results that may be important to an investor. All forward-looking information should be evaluated in the context of these risks, uncertainties and other factors, including those factors disclosed under “Risk Factors” in Recon’s most recent Annual Report on Form 20‑F and any subsequent half-year financial filings on Form 6‑K filed with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by the cautionary statements that Recon makes from time to time in its SEC filings and public communications. Recon cannot assure the reader that it will realize the results or developments Recon anticipates, or, even if substantially realized, that they will result in the consequences or affect Recon or its operations in the way Recon expects. Forward-looking statements speak only as of the date made. Recon undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances arising after the date on which they were made, except as otherwise required by law. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included herein or that may be made elsewhere from time to time by, or on behalf of, Recon.

For more information, please contact:

The Company
Ms. Liu Jia
Chief Financial Officer
Recon Technology, Ltd
Phone: +86 (10) 8494-5799
Email: info@recon.cn

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.